Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Expands By 94.6%

Posted by Doug Madison on Jan 15th, 2025

Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 144,200 shares, a growth of 94.6% from the December 15th total of 74,100 shares. Currently, 1.2% of the shares of the company are short sold. Based on an average daily volume of 55,400 shares, the days-to-cover ratio is presently 2.6 days.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Akari Therapeutics in a research report on Monday. They set a “sell” rating on the stock.

Get Our Latest Report on Akari Therapeutics

Akari Therapeutics Stock Down 5.0 %

Shares of AKTX opened at $1.15 on Wednesday. Akari Therapeutics has a 52 week low of $0.90 and a 52 week high of $4.40. The company’s 50 day moving average price is $1.36 and its 200 day moving average price is $2.57.

Akari Therapeutics Company Profile

(Get Free Report)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.